New Blood Test Offers Faster and More Accurate Tuberculosis Detection

Tuberculosis (TB) remains a major global health threat, killing over a million people every year.

Furthermore, current blood tests cannot distinguish between latent TB, where the bacteria are dormant, and active TB, which is contagious.

New blood tests are being developed to identify active TB by detecting specific antibodies or cell-free DNA markers.

Technologies like CRISPR-based assays allow for rapid, real-time detection, often delivering results in as little as 30 to 120 minutes.

These innovative tests are particularly promising for pediatric care, where providing sputum samples is often impossible, and for remote areas where laboratory access is limited.

This shift toward faster, non-invasive, and point-of-care diagnostics is a crucial step in the global strategy to eliminate tuberculosis by 2030, ultimately saving countless lives through earlier and more precise medical intervention.